Pricing & Access· August 17, 2026 · 25 min read
Medicaid's September 10 Deadline: The Coverage Trade for GENEROUS Pricing
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Topic
Formulary Strategy
Tiering, exclusions, preferred products, step therapy, and how access teams prepare the evidence packet.
Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Specialty· August 15, 2026 · 25 min read
Kidney Transplant Immunosuppression: Part B-ID Cliff, Tacrolimus, & Access
By Ran Chen#Nephrology#Medicare Part B#Coverage Access
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Policy· August 12, 2026 · 38 min read
IARC Group 1 Call on HCTZ, Voriconazole, Tacrolimus: Pharma & P&T Actions
By Ran Chen#FDA#Label Warnings#Formulary Strategy
Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy
Specialty· July 30, 2026 · 20 min read
Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics
Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics
Approvals· July 16, 2026 · 17 min read
Lipfendra (enlicitide) coverage: first oral PCSK9 inhibitor approval
By Ran Chen#Cardiovascular#PCSK9#FDA Approval